

PROTOCOL CODE: GOCXCPNBP

(Page 1 of 3)

DOCTOR'S ORDERS		Ht _____ cm	Wt _____ kg	BSA _____ m ²									
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form													
DATE:	To be given:	Cycle #:											
Date of Previous Cycle:													
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff, Platelets on day of treatment													
<p>May proceed with doses as written if within 96 hours ANC greater than or equal to 1.0 x 10⁹/L, Platelets greater than or equal to 100 x 10⁹/L, creatinine less than or equal to 1.5 times the upper limit of normal and less than or equal to 1.5 times the baseline, ALT less than or equal to 3 times the upper limit of normal, total bilirubin less than or equal to 1.5 times the upper limit of normal, BP less than or equal to 150/100, and urine dipstick for protein negative or 1+.</p> <p>Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity _____</p> <p>Proceed with treatment based on blood work from _____</p>													
<p>PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.</p> <p>For prior pembrolizumab infusion reaction:</p> <input type="checkbox"/> diphenhydramine 50 mg PO 30 minutes prior to pembrolizumab <input type="checkbox"/> acetaminophen 325 to 975 mg PO 30 minutes prior to pembrolizumab <input type="checkbox"/> hydrocortisone 25 mg IV 30 minutes prior to pembrolizumab													
<p>dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO 30 to 60 minutes prior to CARBOplatin</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%; padding: 5px;">AND select ONE of the following:</td> <td style="width: 5%; padding: 5px;"><input type="checkbox"/></td> <td style="padding: 5px;">ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin</td> </tr> <tr> <td style="padding: 5px;"></td> <td style="padding: 5px;"><input type="checkbox"/></td> <td style="padding: 5px;">aprepitant 125 mg PO 30 to 60 minutes prior to CARBOplatin, and ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin</td> </tr> <tr> <td style="padding: 5px;"></td> <td style="padding: 5px;"><input type="checkbox"/></td> <td style="padding: 5px;">netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CARBOplatin</td> </tr> </table>					AND select ONE of the following:	<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin		<input type="checkbox"/>	aprepitant 125 mg PO 30 to 60 minutes prior to CARBOplatin, and ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin		<input type="checkbox"/>	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CARBOplatin
AND select ONE of the following:	<input type="checkbox"/>	ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin											
	<input type="checkbox"/>	aprepitant 125 mg PO 30 to 60 minutes prior to CARBOplatin, and ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin											
	<input type="checkbox"/>	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to CARBOplatin											
<p>If additional antiemetic required:</p> <input type="checkbox"/> OLANzapine <input type="checkbox"/> 2.5 mg or <input type="checkbox"/> 5 mg or <input type="checkbox"/> 10 mg (select one) PO 30 to 60 minutes prior to CARBOplatin <input type="checkbox"/> Other:													
Continued on page 2													
DOCTOR'S SIGNATURE:				SIGNATURE:									
				UC:									

PROTOCOL CODE: GOCXCPNBP

(Page 2 of 3)

DOCTOR'S ORDERS		Page 2 of 3						
DATE:	To be given:	Cycle #:						
Have Hypersensitivity Reaction Tray and Protocol Available								
TREATMENT:								
<p>pembrolizumab 2 mg/kg x _____ kg = _____ mg (max. 200 mg) IV in 50 mL NS over 30 minutes using a 0.2 micron in-line filter*</p>								
<p>PAClitaxel NAB (ABRAXANE) 260 mg/m² x BSA = _____ mg <input type="checkbox"/> Dose Modification: _____ % = _____ mg IV over 30 minutes (in empty sterile PVC, non-PVC or non-DEHP bag and tubing; use tubing with 15 micron filter*)</p>								
<p>CARBOplatin AUC 5 x (GFR + 25) x = _____ mg <input type="checkbox"/> Dose Modification: _____ % = _____ mg IV in 100 to 250 mL NS over 30 minutes. Blood pressure measurement pre-bevacizumab dose.</p>								
<p>bevacizumab <input type="checkbox"/> 15 mg/kg or <input type="checkbox"/> _____ mg/kg (<i>select one</i>) x _____ kg = _____ mg IV in 100 to 250 mL NS over 30 minutes (first infusion over 1 hour). (Blood pressure measurement post-bevacizumab infusion for first 3 cycles)</p>								
Pharmacy to select bevacizumab brand as per Provincial Systemic Therapy Policy III-190								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%; padding: 5px;">Drug</th> <th style="width: 40%; padding: 5px;">Brand (Pharmacist to complete. Please print.)</th> <th style="width: 40%; padding: 5px;">Pharmacist Initial and Date</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">bevacizumab</td> <td style="padding: 5px;"></td> <td style="padding: 5px;"></td> </tr> </tbody> </table>	Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date	bevacizumab				
Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date						
bevacizumab								
* use separate infusion line and filter for each drug								
DOCTOR'S SIGNATURE:		SIGNATURE: UC:						



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOCXCPNBP

(Page 3 of 3)

DATE:	Page 3 of 3	
RETURN APPOINTMENT ORDERS		
Return in three weeks for Doctor and Cycle _____ <input type="checkbox"/> Last Cycle. Return in three weeks for GOCXPB or GOCXPB6 (to continue pembrolizumab with or without bevacizumab)		
<p>CBC & Diff, Platelets, creatinine, ALT, alkaline phosphatase, total bilirubin, sodium, potassium, TSH, dipstick or laboratory urinalysis for protein, blood pressure measurement prior to each cycle.</p> <input type="checkbox"/> 24 hr urine for total protein within 3 days prior to next bevacizumab dose if 2+ or 3+ dipstick or greater than or equal to 1 g/L laboratory urinalysis for protein <input type="checkbox"/> INR weekly <input type="checkbox"/> INR prior to next cycle		
If clinically indicated: <input type="checkbox"/> ECG <input type="checkbox"/> Chest X-ray		
<input type="checkbox"/> serum HCG or urine HCG – required for woman of child bearing potential <input type="checkbox"/> Free T3 and free T4 <input type="checkbox"/> lipase <input type="checkbox"/> morning serum cortisol <input type="checkbox"/> random glucose <input type="checkbox"/> GGT <input type="checkbox"/> total protein <input type="checkbox"/> albumin <input type="checkbox"/> creatine kinase <input type="checkbox"/> serum ACTH levels <input type="checkbox"/> testosterone <input type="checkbox"/> estradiol <input type="checkbox"/> FSH <input type="checkbox"/> LH <input type="checkbox"/> Weekly nursing assessment <input type="checkbox"/> Other consults <input type="checkbox"/> See general orders sheet for additional requests.		
DOCTOR'S SIGNATURE:		SIGNATURE:
		UC: